A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status:
Active, not recruiting
Trial end date:
2024-06-24
Target enrollment:
Participant gender:
Summary
This study is designed to select up to two doses of baricitinib (referred to as low dose and
high dose) and assess their efficacy and safety for the treatment of severe or very severe
alopecia areata.